Table 2.
Patient-, tumor- and treatment characteristics of patients treated with first-line BRAF-MEK inhibitors not reaching long-term survival versus 2-,3-,4- and 5-year survivors
| Patients surviving <2 years | Patients surviving >2 years | Patients surviving >3 years | Patients surviving >4 years | Patients surviving >5 years | |
|---|---|---|---|---|---|
| Patients; n | 319 | 116 | 88 | 47 | 14 |
| Median age, year (range) | 59 (19–88) | 58 (27, 91) | 58 (27–91) | 57 (34–86) | 51 (36–84) |
| Gender; n (%) | |||||
| Male | 173 (54.2) | 56 (48.3) | 44 (50.0) | 18 (38.3) | 6 (42.9) |
| Female | 146 (45.8) | 60 (51.7) | 44 (50.0) | 29 (61.7) | 8 (57.1) |
| ECOG PS; n (%) | |||||
| 0 | 96 (30.1) | 55 (47.4) | 43 (48.9) | 29 (61.7) | 11 (78.6) |
| 1 | 110 (34.5) | 41 (35.3) | 33 (37.5) | 12 (25.5) | 2 (14.3) |
| ≥2 | 76 (23.8) | 14 (12.1) | 9 (10.2) | 3 (6.4) | 0 (0.0) |
| Unknown | 37 (11.6) | 6 (5.2) | 3 (3.4) | 3 (6.4) | 1 (7.1) |
| LDH level U/l; n (%) | |||||
| Normal | 140 (43.9) | 69 (59.5) | 54 (61.4) | 30 (63.8) | 10 (71.4) |
| 250–500 | 98 (30.7) | 39 (33.6) | 29 (33.0) | 14 (29.8) | 3 (21.4) |
| >500 | 74 (23.2) | 4 (3.4) | 2 (2.3) | 1 (2.1) | 0 (0.0) |
| Not determined | 7 (2.2) | 4 (3.4) | 3 (3.4) | 2 (4.3) | 1 (7.1) |
| Stage (AJCC 7th); n (%) | |||||
| IIIc | 12 (3.8) | 19 (16.4) | 16 (18.2) | 9 (19.1) | 3 (21.4) |
| IV-M1a | 5 (1.6) | 9 (7.8) | 9 (10.2) | 5 (10.6) | 2 (14.3) |
| IV-M1b | 5 (1.6) | 7 (6.0) | 5 (5.7) | 4 (8.5) | 1 (7.1) |
| IV-M1c | 297 (93.1) | 81 (69.8) | 58 (65.9) | 29 (61.7) | 8 (57.1) |
| Metastasis in ≥3 organ sites; n (%) | 224 (70.2) | 47 (40.5) | 32 (36.4) | 15 (31.9) | 4 (28.6) |
| Brain metastasis; n (%) | |||||
| No | 149 (46.7) | 70 (60.3) | 54 (61.4) | 30 (63.8) | 10 (71.4) |
| Yes, asymptomatic | 44 (13.8) | 10 (8.6) | 6 (6.8) | 4 (8.5) | 1 (7.1) |
| Yes, symptomatic | 109 (34.2) | 15 (12.9) | 11 (12.5) | 4 (8.5) | 0 (0.0) |
| Unknown | 17 (5.3) | 21 (18.1) | 17 (19.3) | 9 (19.1) | 3 (21.4) |
| Liver metastasis; n (%) | 139 (43.6) | 24 (20.7) | 16 (18.2) | 7 (14.9) | 2 (14.3) |
| Best overall response; n (%) | |||||
| Complete response | 7 (2.2) | 30 (25.9) | 29 (33.0) | 19 (40.4) | 5 (35.7) |
| Partial response | 191 (59.9) | 66 (56.9) | 44 (50.0) | 18 (38.3) | 6 (42.9) |
| Stable disease | 64 (20.1) | 14 (12.1) | 10 (11.4) | 6 (12.8) | 3 (21.4) |
| Progressive disease | 43 (13.5) | 6 (5.2) | 5 (5.7) | 4 (8.5) | 0 (0.0) |
| LTFU | 14 (4.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| BRAF mutation; n (%) | |||||
| V600E | 269 (84.3) | 92 (79.3) | 68 (77.3) | 37 (78.7) | 12 (85.7) |
| V600K | 43 (13.5) | 18 (15.5) | 15 (17.0) | 7 (14.9) | 2 (14.3) |
| Other | 7 (2.2) | 6 (5.2) | 5 (5.7) | 3 (6.4) | 0 (0.0) |
| Subsequent therapy after first-line BRAF-MEK; n (%) | |||||
| No | 158 (49.5) | 34 (29.3) | 27 (30.7) | 16 (34.0) | 6 (42.9) |
| Immunotherapy | 151 (47.3) | 75 (64.7) | 57 (64.8) | 28 (59.6) | 8 (57.1) |
| Other | 9 (2.8) | 7 (6.0) | 4 (4.5) | 3 (6.4) | 0 (0.0) |
AJCC, American Joint Committee on Cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Score; LDH, lactate dehydrogenase.